Cartilage Repair Market

The global Cartilage Repair/Cartilage Regeneration Market is projected to reach USD 2.8 billion by 2028 from USD 1.3 billion in 2023, at a CAGR of 17.2% during the forecast period. Growth in this market is mainly driven by the increasing prevalence of osteoarthritis, the increasing number of sports and accident-related orthopedic injuries and technological advancements cartilage repair market.

The Cartilage Repair/Cartilage Regeneration Market is consolidated and is dominated by various players. The major players operating in this market are Smith+Nephew (UK), DePuy Synthes (Johnson & Johnson) (US), Zimmer Biomet Holdings, Inc.(US), Stryker Corporation (US) and Vericel Corporation (US). These include product launches, contracts, partnerships, mergers and acquisitions, and new product development activities to further expand their presence in the Cartilage Repair/Cartilage Regeneration Market.

To know about the assumptions considered for the study download the pdf brochure

Smith+Nephew (UK) has strong distribution channels and a good brand image. The revenue in 2022 was USD 5,215 million, an increase of 0.1% on a reported basis and 4.7% on an underlying basis. Recently In November the company entered into a definitive agreement to acquire CartiHeal, the developer of Agili-C, a novel sports medicine technology for cartilage regeneration in the knee. Smith+Nephew will pay an initial cash consideration of USD 180 million at closing and up to a further USD 150 million contingent on financial performance. The acquisition of this disruptive technology will support the strategy to invest in a successful Sports Medicine business. Agili-C is the perfect addition to the portfolio and will help the company in leveraging expertise to transform cartilage repair outcomes for patients.

Vericel Corporation (US) is a fully integrated, commercial-stage biopharmaceutical company and a leader in advanced fully integrated sports medicine and severe burn care markets. The company offers MACI (autologous cultured chondrocytes on porcine collagen membrane) is an autologous cellularized scaffold product for cartilage defects. In the last five years through 2022, MACI sales volumes from the first through the fourth quarter have on average represented of total annual volumes as 20%, 21%, 24% and 35% respectively. The effects of the COVID-19 pandemic impacted the sale in 2022 and 2021.

DePuy Synthes (Johnson & Johnson) (US) has achieved full-year operational sales growth of more than 6%. Therefore, the Company has invested nearly USD 15 billion in R&D, and deployed more than USD 17 billion toward acquisitions. DePuy Synthes offers the COR Precision Targeting System as a single patient using pre-sterile Osteochondral Autograft Transfer System featuring “No Impact Transfer” and “Low Impact Delivery” for protection of chondrocyte viability.

Zimmer Biomet Holdings, Inc. (US) offers products for cartilage repair as  DeNovo NT Graft which is a cartilage implant for treating articular cartilage damage repair. The company had a net sales of USD 6.940 billion in 2022 as compared to 2021 which increased by 1.6%.

Stryker Corporation (US): In 2022, the company had a net sales growth of 7.8%. Therefore the sales grew 9.7% in constant currency. The company offers ProChondrix CR an osteochondral allograft containing live cells and other biological components used for cartilage repair.

Related Reports:

Cartilage Repair/Cartilage Regeneration Market by Treatment Modalities (Cell-Based (Chondrocyte Transplantation, Stem Cells, Growth Factors), Non-Cell (Tissue Scaffolds)), Application (Hyaline, Fibrocartilage), Site, and Region - Global Forecast to 2028

Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
[email protected]